Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials.

<h4>Background</h4>The RV144 clinical trial showed for the first time that vaccination could provide modest but significant protection from HIV-1 infection. To understand the protective response, and to improve upon the vaccine's efficacy, it is important to define the structure of...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Bin Yu, Javier F Morales, Sara M O'Rourke, Gwen P Tatsuno, Phillip W Berman
Format: article
Langue:EN
Publié: Public Library of Science (PLoS) 2012
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/34b4ba247fa246ce969cefb256a8b7db
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!